Last reviewed · How we verify
Acetaminophen solid formulation
Acetaminophen exerts its analgesic and antipyretic effects primarily through inhibition of cyclooxygenase (COX) enzymes, leading to reduced prostaglandin synthesis.
Acetaminophen exerts its analgesic and antipyretic effects primarily through inhibition of cyclooxygenase (COX) enzymes, leading to reduced prostaglandin synthesis. Used for Mild to moderate pain, Fever.
At a glance
| Generic name | Acetaminophen solid formulation |
|---|---|
| Sponsor | Beth Israel Deaconess Medical Center |
| Drug class | analgesic |
| Target | cyclooxygenase (COX) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | Phase 1 |
Mechanism of action
Acetaminophen's mechanism of action involves the inhibition of COX enzymes, which are responsible for the production of prostaglandins. Prostaglandins play a key role in pain and fever pathways, and their reduction leads to the therapeutic effects of acetaminophen.
Approved indications
- Mild to moderate pain
- Fever
Common side effects
- Nausea
- Headache
- Dizziness
Key clinical trials
- Protective Effects of Propylene Glycol in Daily Acetaminophen Dosing (PHASE4)
- Effect on Acetaminophen Metabolism by Liquid Formulations (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Acetaminophen solid formulation CI brief — competitive landscape report
- Acetaminophen solid formulation updates RSS · CI watch RSS
- Beth Israel Deaconess Medical Center portfolio CI